Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | FADS1 | O60427 | 1/20 | 0.46 |
| ▸ | RORB | Q92753 | 4/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13758149 | 0.85 | RECQL (0.54) | RECQLALDH1A1MAPTCES2CES1 | |
| SCHEMBL3821668 | 0.84 | RECQL (0.52) | RECQLALDH1A1MAPTCES2CES1 | |
| SCHEMBL3823928 | 0.84 | LMNA (0.55) | RECQLALDH1A1MAPTCES2CES1 | |
| SCHEMBL11019993 | 0.81 | RECQL (0.71) | RECQLALDH1A1CES2CES1TP53 | |
| SCHEMBL14159770 | 0.81 | RECQL (0.65) | RECQLALDH1A1CES2CES1RORB | |
| SCHEMBL4707059 | 0.80 | RECQL (0.73) | RECQLALDH1A1MAPTCES2CES1 | |
| SCHEMBL31272816 | 0.80 | RECQL (0.73) | RECQLALDH1A1MAPTCES2CES1 | |
| SCHEMBL2189708 | 0.80 | ALDH1A1 (0.57) | RECQLALDH1A1MAPTCES2CES1 | |
| SCHEMBL3820762 | 0.79 | RECQL (0.63) | RECQLALDH1A1CES2CES1TP53 | |
| SCHEMBL2704116 | 0.79 | ALDH1A1 (0.59) | RECQLALDH1A1MAPTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101039946-B | Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogenesis and for the treatment of breast, colon, lung and prostate cancer | HOFFMANN LA ROCHE | 2010-12-08 | — | — | CN | disclosed |
| CN-101899049-A | Disubstituted pyrazole and benzodiazepines class | HOFFMANN LA ROCHE | 2010-12-01 | — | — | CN | disclosed |
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1802625-B1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1802625-B1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | disclosed |
| CN-101039946-A | Disubstituted pyrazolobenzodiazepines * useful as inhibitors for CDK2 and angiogenesis and for the treatment of breast, colon, lung and prostate cancer | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | CN | disclosed |
| EP-1802625-A1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040036-A1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079511-A1 | 7,8-Disubstituted pyrazolobenzodiazepines | LIU JIN-JUN | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079511-A1 | 7,8-Disubstituted pyrazolobenzodiazepines | CDK2, CDK1, CDK7 | RECQL 1534/4885ALDH1A1 2432/4885MAPT 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.